Marker Therapeutics, Inc. Common Stock MRKR
Key Stats
- Today's Range
- $1.11 – $1.21
- 50-Day Range
- $1.11 – $1.72
- 52-Week Range
- $0.81 – $4.07
- Volume
- 39K shs
- Average Volume
- 58K shs
- Market Cap
- $19.67 million
- P/E Ratio
- —
- Dividend Yield
- —
Valuation
- P/E Ratio
- —
- Price / Book
- 1.43
- Price / Sales
- 4.98
Short Interest
- Short Interest
- 8.47%
- Days to Cover
- 7.76
Financials (TTM)
- Revenue
- $3.95 million
- Net Income
- $-10,896,714
- Net Margin
- -275.92%
- Return on Equity
- -78.98%
- Debt-to-Equity
- —
About Marker Therapeutics, Inc. Common Stock
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from MAR-T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. Its pipeline products include: Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601), and Off-the-Shelf (OTS) products (MT-401-OTS).
Related Stocks
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.